Filing Details
- Accession Number:
- 0001022079-17-000009
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-02-06 16:36:55
- Reporting Period:
- 2017-02-02
- Filing Date:
- 2017-02-06
- Accepted Time:
- 2017-02-06 16:36:55
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1022079 | Quest Diagnostics Inc | DGX | Services-Medical Laboratories (8071) | 161387862 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1222679 | E Michael Prevoznik | C/O Quest Diagnostics Incorporated 3 Giralda Farms Madison NJ 07940 | Svp & General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-02-02 | 30,000 | $51.20 | 71,918 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-02-02 | 30,000 | $92.40 | 41,918 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2017-02-02 | 15,000 | $55.65 | 56,918 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-02-02 | 15,000 | $92.38 | 41,986 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2017-02-02 | 30,000 | $51.20 | 30,000 | $51.20 |
| Common Stock | Stock Options (Right to Buy) | Disposition | 2017-02-02 | 15,000 | $55.65 | 15,000 | $55.65 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2019-02-11 | No | 4 | M | Direct | |
| 15,000 | 2020-02-10 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 4,809 | Indirect | 401(k)/SDCP |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $92.08 to $92.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $92.06 to $92.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
- These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
- The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.
Billionaire Hedge Funds
